Cohen Investment Advisors LLC Has $2.94 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cohen Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,917 shares of the medical research company's stock after purchasing an additional 941 shares during the period. Thermo Fisher Scientific comprises about 1.7% of Cohen Investment Advisors LLC's investment portfolio, making the stock its 27th biggest holding. Cohen Investment Advisors LLC's holdings in Thermo Fisher Scientific were worth $2,944,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Cypress Advisory Group LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $253,000. Intact Investment Management Inc. raised its stake in Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after acquiring an additional 660 shares during the period. GAMMA Investing LLC raised its stake in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after acquiring an additional 877 shares during the period. Deutsche Bank AG raised its stake in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after acquiring an additional 114,277 shares during the period. Finally, Hancock Whitney Corp raised its stake in Thermo Fisher Scientific by 0.6% during the fourth quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock worth $2,802,000 after acquiring an additional 30 shares during the period. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 0.1%

Shares of NYSE:TMO traded up $0.49 during trading on Friday, reaching $428.25. 1,359,321 shares of the company traded hands, compared to its average volume of 1,974,470. The firm has a market cap of $161.66 billion, a P/E ratio of 25.12, a price-to-earnings-growth ratio of 2.28 and a beta of 0.77. The firm has a fifty day simple moving average of $409.18 and a 200 day simple moving average of $479.65. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the firm earned $5.11 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Analyst Upgrades and Downgrades

Several brokerages have commented on TMO. Argus dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $604.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.